Tokyo, Japan, March 15, 2024 – United Immunity, a biotech company developing nanogels and lipid nanoparticles based on its Myeloid Targeting PlatformTM, announced today that it has secured ￥180 million (~ $1.2 million) venture debt financing from Aozora Corporate Investment.

Debt financing of deep tech companies including biotech in Japan is historically challenging. However, Aozora Corporate Investment decided to invest in United Immunity after evaluating the company’s innovative drug delivery platform and its lead drug candidate UI-102 for the treatment of immune resistant cold solid tumor.

The company will use the proceeds to accelerate development and partnering of its Myeloid Targeting PlatformTM and bring UI-102 from preclinical stage to Phase 1 clinical studies.